TRIP6 Antibody (G-11): sc-376303

TRIP6 Antibody (G-11) is a mouse monoclonal IgG2b antibody that detects TRIP6 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). TRIP6 is a LIM domain-containing protein that plays a critical role in cellular signaling and cytoskeletal organization, particularly at focal adhesion sites where TRIP6 interacts with various signaling molecules. TRIP6 is essential for mediating the effects of tumor necrosis factor (TNF) and interleukin-1 (IL-1) signaling pathways, which are pivotal in inflammatory responses and cellular stress. TRIP6′s ability to interact with receptor-interacting protein 2 (RIP2) and other key proteins like TRAF2 enhances TRIP6′s role in activating the NF-kappaB pathway, a crucial mechanism for regulating immune responses and cell survival. The localization of TRIP6 at focal adhesions underscores TRIP6′s importance in linking extracellular signals to the cytoskeleton, thereby influencing cell migration and adhesion. With versatile applications and significant biological functions, anti-TRIP6 antibody (G-11) is an invaluable tool for researchers studying cellular signaling and the molecular mechanisms underlying various diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

TRIP6 Antibody (G-11) References:

1. Restriction to Fos family members of Trip6-dependent coactivation and glucocorticoid receptor-dependent trans-repression of activator protein-1.  |  Diefenbacher, M., et al. 2008. Mol Endocrinol. 22: 1767-80. PMID: 18535250
2. The nuclear isoform of the LIM domain protein Trip6 integrates activating and repressing signals at the promoter-bound glucocorticoid receptor.  |  Diefenbacher, ME., et al. 2010. Mol Cell Endocrinol. 320: 58-66. PMID: 20153803
3. The Zyxin-related protein thyroid receptor interacting protein 6 (TRIP6) is overexpressed in Ewing's sarcoma and promotes migration, invasion and cell growth.  |  Grunewald, TG., et al. 2013. Biol Cell. 105: 535-47. PMID: 24033704
4. MicroRNA‑138‑5p regulates neural stem cell proliferation and differentiation in vitro by targeting TRIP6 expression.  |  Wang, J., et al. 2017. Mol Med Rep. 16: 7261-7266. PMID: 28944841
5. TRIP6 promotes tumorigenic capability through regulating FOXC1 in hepatocellular carcinoma.  |  Wang, F., et al. 2020. Pathol Res Pract. 216: 152850. PMID: 32046874
6. TRIP6 is required for tension at adherens junctions.  |  Venkatramanan, S., et al. 2021. J Cell Sci. 134: PMID: 33558314
7. TRIP6 functions in brain ciliogenesis.  |  Shukla, S., et al. 2021. Nat Commun. 12: 5887. PMID: 34620853
8. TRIP6 disrupts tight junctions to promote metastasis and drug resistance and is a therapeutic target in colorectal cancer.  |  Gou, H., et al. 2023. Cancer Lett. 578: 216438. PMID: 37827326
9. TRIP6 a potential diagnostic marker for colorectal cancer with glycolysis and immune infiltration association.  |  Liu, XS., et al. 2024. Sci Rep. 14: 4042. PMID: 38369589
10. Construction of an immune predictive model and identification of TRIP6 as a prognostic marker and therapeutic target of CRC by integration of single-cell and bulk RNA-seq data.  |  Liu, W., et al. 2024. Cancer Immunol Immunother. 73: 69. PMID: 38430268

The preferred TRIP6 antibody is TRIP6 Antibody (F-5): sc-365122.